Psychiatric Co-morbidity in Ketamine and Methamphetamine Dependence: a Retrospective Chart Review

Wai Kwong Tang, Huajun Liang, Yong Lin, Chenxi Zhang, Alan Tang, Fu Chan, Tom P. Freeman, Gabor S. Ungvari

Research output: Contribution to journalArticle

34 Downloads (Pure)

Abstract

Both ketamine and methamphetamine (MA) have become very popular and have been abused worldwide over the past two decades. However, the relationship between dependence on ketamine or MA and psychiatric comorbidities is still unclear. This study aimed to examine the frequency of co-morbid psychiatric disorders in patients dependent on ketamine or methamphetamine who were receiving treatment at three substance abuse treatment clinics (SACs) in Hong Kong. This was a retrospective chart review. The medical records of 183 patients (103 with ketamine and 80 with MA dependence) treated between January 2008 and August 2012 were retrieved. Patients’ demographic data, patterns of substance abuse and comorbid psychiatric diagnoses were recorded. The mean age of onset and duration of substance abuse were 18.1 ± 4.7 and 9.2 ± 6.2 years for ketamine and 19.9 ± 8.8 and 10.5 ± 9.8 years for MA users, respectively. Psychotic disorders were more common in MA dependent users (76.2 % vs. 28.2 %, p < 0.001), whereas mood disorders were more common in ketamine dependent users (27.2 % vs. 11.2 %, p = 0.008). Ketamine and MA dependence have a notably different profile of psychiatric co-morbidity. Compared with MA dependence, ketamine dependence is more likely to be associated with mood disorders and less likely with psychotic disorders.

Original languageEnglish
Pages (from-to)956-966
Number of pages11
JournalInternational Journal of Mental Health and Addiction
Volume15
Issue number4
Early online date3 Oct 2016
DOIs
Publication statusPublished - 1 Aug 2017

    Fingerprint

Keywords

  • Co-morbidity
  • Ketamine
  • Methamphetamine
  • Mood disorders
  • Psychotic disorders

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this